Krsnaa Diagnostics Limited (KRSNAA)
Investor Presentation
Investor Presentation - Q1 FY27
- Revenue 2,355mn +22% y-y; EBITDA 588mn +12% y-y; EBITDA margin 25% (-221 bps); PAT 166mn -19% y-y
- Retail revenue up 64% y-y, patient count +75%, test volume +47%, retail revenue contribution 8%
- NABH accreditation doubled to 66 centres; NABL labs stable at 54
- Network expanded: 200+ CT/MRI centres, 8,400+ patient touch points across 19 states
- Margin moderation due to upfront fixed costs in Rajasthan labs ahead of full utilisation
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 KRSNAA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add KRSNAA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Krsnaa Diagnostics Limited
Important.
The summary above is generated automatically from Krsnaa Diagnostics Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.